Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1SF2 p17) and peptide segments of human β-2-microglobulin or MHC II β chain

Vaccine

Volumn 19, Issue 32, 2001, Pages 4750-4759

  Zimmerman, D H ^a   Lloyd, J P ^a   Heisey, D ^a   Winship, M D ^a   Siwek, M ^a   Talor, E ^a   Sarin, P S ^a  

^a CEL SCI Corporation   (United States)

Author keywords

HGP 30; HIV 1; HIV 1 antibodies; MHC II chain; p17; Peptide conjugate; Vaccine; 2 Microglobulin

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; BETA 2 MICROGLOBULIN; FREUND ADJUVANT; HGP 30; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; KEYHOLE LIMPET HEMOCYANIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONTANIDE; MPL; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BETA CHAIN; CELLULAR IMMUNITY; CONJUGATE; CONTROLLED STUDY; CROSS REACTION; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ALUM COMPOUNDS; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY SPECIFICITY; BETA 2-MICROGLOBULIN; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; H-2 ANTIGENS; HEMOCYANIN; HIV ANTIGENS; HLA-D ANTIGENS; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED STRAINS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDES; SPECIES SPECIFICITY; TIME FACTORS;

EID: 0035860621     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00247-X     Document Type: Article

References (66)

1. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
2. Virus specific CD8+ cytotoxic T lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
3. Characterization of human immunodeficiency virus type 1 specific cytotoxic T lymphocyte clones isolated during acute seroconversion: Recognition of autologous virus sequences within a conserved immunodominant epitope
4. Kinetics of gag specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long term asymptomatics
5. Escape of human immunodeficiency virus from immune control
6. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable non-progressing HIV type 1 infection
7. HIV specific cellular and humoral immune responses in primary HIV infection
8. Cell mediated immunity in HIV infection
9. Cytotoxic T lymphocytes against HIV
10. A strategy of prophylactic vaccination against HIV
11. Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1 infected individual
12. Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1 infected individual
13. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients
14. DNA inoculation induces protective in vivo immune responses against cellular challenge with HIV-1 antigen-expressing cells
15. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
16. HIV preventive vaccines. Progress to date
17. Re-examining AIDS research priorities
18. Scientific and social issues of human immunodeficiency virus vaccine development
19. 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30
20. Presence of specific antibodies to synthetic epitopes of HIV-1 gag p17 correlates with stages of HIV-1 infection in homosexuals and IV drug abusers
21. HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17 is a target for cytotoxic lymphocytes in HIV infected individuals
22. Safety and immunogenicity of HGP-30. Evaluation of a synthetic HIV-1 p17 vaccine in healthy HIV seronegative volunteers
23. A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue subunit vaccine in seronegative subjects
24. Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17 based synthetic peptide AIDS vaccine HGP-30/KLH
25. HIV-1 p17 synthetic peptide vaccine HGP-30. Induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice
26. Strong immunogenicity of multicomponent peptide vaccine developed with branched lysine oligopeptide method for human immunodeficiency virus
27. Strong synergistic effects of multicomponent vaccine for human immunodeficiency virus infection
28. Neutralization of HIV-1 by secretory IgA induced oral immunization with a new macromolecular multicomponent peptide vaccine candidate
29. Cell mediated immunity against HGP-30, a group specific peptide of HIV p17 in individuals infected with the AIDS virus
30. Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes: Advances in 1994-1995
31. Development of artificial vaccines against HIV using defined epitopes
32. Molecular mimicry by herpes simplex virus-type 1: Autoimmune disease after viral infection
33. Recombinant cytomegalovirus glycoprotein gB (UL55) induces an autoantibody response to the U1-70 kDa small nuclear ribonucleoprotein
34. HIV type 1 envelope glycoprotein 120 carboxy-terminal peptide-induced human T cell lines selectively suppress heterogeneous proliferative T cell responses to soluble antigens
35. Inhibition of lymphokine-activated killer activity during HIV infection: Role of HIV-1 gp41 synthetic peptides
36. A soluble inhibitor of T lymphocyte function induced by HIV-1 infection of CD4+ cells: Characterization of a cellular protein and its relationship to p15E
37. Cross clade p17 peptide recognition by antisera to HGP-30, a thirty amino acid synthetic peptide antigen from HIV-1 p17
38. Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice
39. Approaches and issues in the development of vaccines against HIV
40. New insights and approaches regarding B- and T- cell epitopes in HIV vaccine design
41. The use of peptide heteroconjugates to prime TH1 associated antibodies (IgG2a) directed against an epitope (38.G) of Mycobacterium tuberculosis which recognize the epitope in the 38 kDa protein
42. A new approach to T-cell activation. Natural and synthetic conjugates capable of activating T cells
43. Immunization with a L.E.A.P.S. heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex type 1
44. Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy
45. Immunogenicity of streptococcus pneumoniae type 14 capsular polysaccharide: Influence of carriers and adjuvants on isotype distribution
46. Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate early protein ICP27 of HSV
47. Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides
48. b-restricted HSV-1, and HSV-2-cross reactive cytotoxic T lymphocyte clones
49. M. tuberculosis-complex specific T-cell stimulation and DTH reactions induced with a peptide from the 38-kDa protein
50. Identification of T cell stimulatory peptides from the 38-kDa protein of Mycobacterium tuberculosis
51. Enhanced immunogenicity of a sequence derived from hepatitis B virus surface antigen in a composite peptide that includes the immunostimulatory region of human IL1
52. Bioactive fragment of human IL-1 (163-171) modulates the immune response to synthetic peptides of HIV
53. MHC class II interaction with CD4 medicated by a region analogous to the MHC class I binding site for CD8
54. Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules
55. Arginine 45 is a major part of the antigenic determinant of human β 2-microglobulin recognized by mouse monoclonal antibody BBM1
56. Creating CTL targets with epitope-linked beta-2 microglobulin constructs
57. Covalent linkage to beta2-microglobulin enhances the MHC stability and antigenicity of suboptimal CTL epitopes
58. Soluble class I MHC with beta2-microglobulin covalently linked peptides: Specific binding to a T cell hybridoma
59. Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants
60. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site
61. Construction of synthetic immunogen: Use of new T-helper epitope on malaria circumsporozoite protein
62. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides
63. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo
64. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1
65. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide